Stanley B. Cohen, MD, and Jonathan Kay, MD, provide CME/CE-certified analysis of 2019 APLAR, EULAR, and JCR as reported by Clinical Care Options (CCO)
Leonard H. Calabrese, DO: expert viewpoint on data from 2019 APLAR, EULAR, and JCR including discussion of investigational and approved agents for RA
Rheumatoid arthritis highlights from EULAR, APLAR, JCR 2019. Chosen by expert faculty and reported by Clinical Care Options.
Latest data on safety of upadacitinib from the SELECT phase III RA program in patients with RA. From EULAR 2019 as reported by Clinical Care Options.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.